Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06281938 |
Other study ID # |
1617209 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 2026 |
Est. completion date |
September 2027 |
Study information
Verified date |
March 2024 |
Source |
Florida Atlantic University |
Contact |
Richard Shih, MD |
Phone |
561 297 3000 |
Email |
rshih[@]health.fau.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The goal of this randomized controlled clinical trial is to [learn about, test, compare etc.]
in critically ill or injured cohorts of patients presenting to the Emergency Department. The
main question[s] it aims to answer are:
- Are weight estimates from a 3D camera system more accurate than standard methods of
weight estimation?
- Do patients who receive weight estimates with a 3D camera system have fewer drug dosing
errors than patients receiving standard care?
Participants will either receive a weight estimate using a 3D camera system, or standard
methods of care.
Researchers will compare the 3D camera group to those with standard care to see if the weight
estimates are more accurate, to see if drug dosing is more accurate, and to compare the
incidence of adverse events related to medications in each group.
Description:
Drug dosing errors can have a catastrophic effect in acutely ill patients such as stroke
patients needing thrombolytic therapy or patients requiring urgent sedation. In an acutely
ill patient, inaccurate weight estimates are a significant cause of dosing errors, and weight
estimates that deviate by >10% from actual weight could make treatment itself life
threatening. Inaccurate weight estimates lead to inaccurate drug doses, which can result in
potentially fatal treatment failure (from subtherapeutic doses) or potentially fatal adverse
events (from supratherapeutic doses). Nearly 75% of treatment failures in obese patients may
be related to errors in weight estimation. When clinical care is time-sensitive, it may be
impossible to obtain a measured weight in >50% of patients. In these circumstances, a rapid,
accurate method for estimating weight is critical. One recent innovation is the use of a
low-cost 3D camera system to estimate weight. The 3D camera device (e.g., Intel RealSense
D415) is used to obtain a point cloud map of the patient's body, from which a weight estimate
can be estimated based on algorithms derived using convoluted neural network analysis.
Initial studies have been extremely promising in terms of the accuracy achievable by this
system in estimating Total Body Weight (TBW).
The primary aim of this study is to measure the accuracy of weight estimations by the 3D
camera system in acutely ill or injured ED patients and compare this accuracy against that of
standard care. The researchers will compare the performance and downstream effects of weight
estimation using the 3D camera system against standard care in a randomized controlled trial
of acutely ill or injured adults presenting to the ED.
The key hypothesis is that the 3D camera system will provide real-time estimates of TBW, IBW
and LBW in an emergency setting and will exceed the accuracy of existing methods of weight
estimation.
Supporting non-clinical trial studies will establish the accuracy of the 3D camera system in
laboratory conditions, and in simulated medical emergencies. However, its performance, and
its impact on downstream drug dosing accuracy, needs to be established during emergency care
in a real clinical setting. This study will provide an essential perspective about the
accuracy and functioning of the 3D camera system as well as real-world weight estimation
during emergency care. It will also describe the ability to measure weight using in-bed
scales and to obtain weight estimations from patients themselves and family members in ED
patients. The secondary objective, to determine the accuracy of drug doses in each arm of the
study, will provide critical information on the need for alternative weight scalars in obese
and morbidly obese patients presenting to the ED. The study will establish the need for
standards and policies to guide dose scaling in obese patients in the ED. Information on the
actual usage of drugs that should be scaled to TBW and those that should be scaled to LBW
will provide useful real-world insight into the magnitude of the problem in the threat to
patient safety by using a "one size fits all" approach to drug dose calculations for all
patients, irrespective of weight status.
Acutely ill patients presenting to the ED of a large regional hospital, and who require
weight-based drug therapy, will be enrolled in the study. They will be randomised to either
receive a weight estimation using a 3D camera system (which will provide estimates of TBW,
IBW and LBW), or to receive standard care. All other interventions and medical care will be
standard care.
These patients will be followed for the first 72 hours of their hospital stay. The accuracy
of the weight estimates will be compared between the groups, as will the drug dose accuracy,
and any adverse events related to drug therapy.